Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 266Lung Neoplasms 102Adenocarcinoma of Lung 28Mesothelioma, Malignant 24Mesothelioma 22Neoplasms 18Meningeal Carcinomatosis 18Brain Neoplasms 16Head and Neck Neoplasms 14Neoplasm Metastasis 13Ovarian Neoplasms 9NSCLC 9Colorectal Neoplasms 8Adenocarcinoma, Bronchiolo-Alveolar 8Breast Neoplasms 7Recurrence 6Carcinoma, Transitional Cell 6Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Lymphoma 5Esophageal Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 4Sarcoma 4Non-squamous Non-small Cell Lung Cancer 4Non-small Cell Lung Cancer Metastatic 4Fallopian Tube Neoplasms 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Stomach Neoplasms 3

Interventions

zirconium-89-trastuzumab 1STA 9090 1Positron-Emission Tomography 1Pemetrexed 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Esophagogastric Cancer × Pemetrexed × Clear all
NCT02296671 2016-03-08

Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers

Washington University School of Medicine

Phase 2 Withdrawn
Gastrointestinal

Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡